Monte Rosa Therapeutics, Inc. (GLUE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 76 | 124 | - | 66 |
| Operating profit | $m | -54 | - | ||||||
| Net profit | $m | -36 | -74 | -109 | -135 | -73 | -39 | - | -84 |
| EPS reported | $ | -0.59 | - | ||||||
| Operating cashflow per share | $ | -0.35 | - | ||||||
| Capex per share | $ | 0.07 | - | ||||||
| FCF per share | $ | -0.42 | - | ||||||
| Free cash flow | $m | -27 | - | ||||||
| Net debt | $m | -342 | - | ||||||
| Book value equity | $m | 233 | - | ||||||
| Book value per share | $ | 3.56 | - | ||||||
| Number of shares | m | 65.54 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.41 | - | ||||||
| P/S LTM | x | 8.31 | - | ||||||
| P/FCF LTM | x | -37.37 | - | ||||||
| EV/EBITDA LTM | x | -29.87 | - | ||||||
| EV/Sales LTM | x | 7.58 | - | ||||||
| Earnings Yield LTM | % | -3.76% | - | ||||||
| FCF Yield | % | -2.68% | - | ||||||
| Quality | |||||||||
| ROE | % | -16.57% | - | ||||||
| ROIC | % | -13.56% | - | ||||||
| Operating margin | % | -43.83% | - | ||||||
| Gross margin | % | +93.24% | - | ||||||
| FCF/Sales | % | -22.23% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +63.54% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.70 | - | ||||||
| Net Debt/EBITDA | x | 2.89 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +3.39% | - | ||||||
| Net debt/Equity | x | -1.47 | - | ||||||
| Gross debt/equity | x | 0.17 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Monte Rosa Therapeutics, Inc. (GLUE)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free